Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AxoGen, Inc. stock logo
AXGN
AxoGen
$12.06
+2.6%
$11.42
$7.34
$21.00
$548.94M1.04501,801 shs354,759 shs
Envista Holdings Corporation stock logo
NVST
Envista
$20.88
+2.5%
$18.49
$14.22
$23.00
$3.54B12.48 million shs449,933 shs
PROCEPT BioRobotics Corporation stock logo
PRCT
PROCEPT BioRobotics
$58.89
+0.7%
$58.14
$47.04
$103.81
$3.26B1.07842,943 shs120,222 shs
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
$125.98
-0.3%
$124.35
$55.00
$177.37
$4.26B2.061.36 million shs245,201 shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AxoGen, Inc. stock logo
AXGN
AxoGen
+2.44%+6.33%+12.97%-25.57%+52.93%
Envista Holdings Corporation stock logo
NVST
Envista
+1.09%+0.94%+7.13%+31.05%+27.47%
PROCEPT BioRobotics Corporation stock logo
PRCT
PROCEPT BioRobotics
+0.95%+0.48%-7.00%+15.24%-10.78%
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
+1.35%-1.00%-9.32%+65.52%-14.46%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AxoGen, Inc. stock logo
AXGN
AxoGen
2.63 of 5 stars
3.52.00.00.01.92.50.6
Envista Holdings Corporation stock logo
NVST
Envista
3.9423 of 5 stars
2.23.00.03.83.80.01.9
PROCEPT BioRobotics Corporation stock logo
PRCT
PROCEPT BioRobotics
2.4571 of 5 stars
3.41.00.00.02.72.50.6
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
1.7124 of 5 stars
1.42.00.00.02.82.51.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AxoGen, Inc. stock logo
AXGN
AxoGen
3.00
Buy$24.50103.10% Upside
Envista Holdings Corporation stock logo
NVST
Envista
2.33
Hold$20.23-3.11% Downside
PROCEPT BioRobotics Corporation stock logo
PRCT
PROCEPT BioRobotics
2.78
Moderate Buy$87.5048.59% Upside
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
2.80
Moderate Buy$127.331.07% Upside

Current Analyst Ratings Breakdown

Latest AXGN, PRCT, NVST, and TMDX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/9/2025
Envista Holdings Corporation stock logo
NVST
Envista
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$19.00 ➝ $23.00
7/9/2025
PROCEPT BioRobotics Corporation stock logo
PRCT
PROCEPT BioRobotics
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$70.00
7/7/2025
PROCEPT BioRobotics Corporation stock logo
PRCT
PROCEPT BioRobotics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageMarket Perform
6/17/2025
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$130.00 ➝ $150.00
6/17/2025
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
6/4/2025
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$125.00 ➝ $145.00
6/3/2025
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
5/27/2025
Envista Holdings Corporation stock logo
NVST
Envista
Baird R W
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
5/27/2025
Envista Holdings Corporation stock logo
NVST
Envista
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Outperform$21.00 ➝ $23.00
5/13/2025
AxoGen, Inc. stock logo
AXGN
AxoGen
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$26.00 ➝ $24.00
5/9/2025
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$125.00 ➝ $130.00
(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AxoGen, Inc. stock logo
AXGN
AxoGen
$187.34M2.93N/AN/A$2.36 per share5.11
Envista Holdings Corporation stock logo
NVST
Envista
$2.50B1.41$1.72 per share12.13$17.05 per share1.22
PROCEPT BioRobotics Corporation stock logo
PRCT
PROCEPT BioRobotics
$224.50M14.51N/AN/A$7.71 per share7.64
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
$488.23M8.73$1.66 per share75.81$6.81 per share18.50
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AxoGen, Inc. stock logo
AXGN
AxoGen
-$9.96M-$0.15N/AN/AN/A-3.68%-7.09%-3.67%8/6/2025 (Estimated)
Envista Holdings Corporation stock logo
NVST
Envista
-$1.12B-$6.53N/A17.261.28-44.90%4.07%2.25%8/6/2025 (Estimated)
PROCEPT BioRobotics Corporation stock logo
PRCT
PROCEPT BioRobotics
-$91.41M-$1.70N/AN/AN/A-36.20%-28.09%-20.02%7/30/2025 (Estimated)
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
$35.46M$1.3692.6288.10N/A10.03%21.88%6.15%7/30/2025 (Estimated)

Latest AXGN, PRCT, NVST, and TMDX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
PROCEPT BioRobotics Corporation stock logo
PRCT
PROCEPT BioRobotics
-$0.41N/AN/AN/AN/AN/A
8/6/2025Q2 2025
Envista Holdings Corporation stock logo
NVST
Envista
$0.24N/AN/AN/A$638.21 millionN/A
7/30/2025Q2 2025
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
$0.48N/AN/AN/A$146.64 millionN/A
5/8/2025Q1 2025
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
$0.29$0.70+$0.41$0.70$123.39 million$143.54 million
5/1/2025Q1 2025
Envista Holdings Corporation stock logo
NVST
Envista
$0.20$0.24+$0.04$0.10$608.17 million$616.90 million
4/24/2025Q1 2025
PROCEPT BioRobotics Corporation stock logo
PRCT
PROCEPT BioRobotics
-$0.49-$0.45+$0.04-$0.45$65.39 million$69.16 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AxoGen, Inc. stock logo
AXGN
AxoGen
N/AN/AN/AN/AN/A
Envista Holdings Corporation stock logo
NVST
Envista
N/AN/AN/AN/AN/A
PROCEPT BioRobotics Corporation stock logo
PRCT
PROCEPT BioRobotics
N/AN/AN/AN/AN/A
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AxoGen, Inc. stock logo
AXGN
AxoGen
0.63
4.28
2.65
Envista Holdings Corporation stock logo
NVST
Envista
0.43
2.12
1.82
PROCEPT BioRobotics Corporation stock logo
PRCT
PROCEPT BioRobotics
0.13
8.95
7.75
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
1.92
9.10
8.32

Institutional Ownership

CompanyInstitutional Ownership
AxoGen, Inc. stock logo
AXGN
AxoGen
80.29%
Envista Holdings Corporation stock logo
NVST
Envista
N/A
PROCEPT BioRobotics Corporation stock logo
PRCT
PROCEPT BioRobotics
89.46%
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
99.67%

Insider Ownership

CompanyInsider Ownership
AxoGen, Inc. stock logo
AXGN
AxoGen
2.78%
Envista Holdings Corporation stock logo
NVST
Envista
1.30%
PROCEPT BioRobotics Corporation stock logo
PRCT
PROCEPT BioRobotics
6.60%
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
7.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
AxoGen, Inc. stock logo
AXGN
AxoGen
45045.54 million44.28 millionOptionable
Envista Holdings Corporation stock logo
NVST
Envista
12,300169.49 million167.28 millionOptionable
PROCEPT BioRobotics Corporation stock logo
PRCT
PROCEPT BioRobotics
43055.33 million51.68 millionOptionable
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
21033.82 million31.46 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
AxoGen stock logo

AxoGen NASDAQ:AXGN

$12.06 +0.30 (+2.58%)
As of 12:43 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

AxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.

Envista stock logo

Envista NYSE:NVST

$20.88 +0.50 (+2.45%)
As of 12:42 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products. This segment also provides software packages, which include DTX Studio Implant; DTX Studio Lab; and DTX Studio Clinic, a software package offered with its imaging products. It offers its products under the Nobel Biocare, Alpha-Bio Tec, Implant Direct, Nobel Procera, Ormco, Spark, Orascoptic, Damon, Insignia, AOA brands. The Equipment & Consumables segment provides dental equipment and supplies, including digital imaging systems, software, and other visualization/magnification systems; endodontic systems and related products; restorative materials, rotary burs, impression materials, bonding agents, and cements; and infection prevention products. This segment offers its products under the Dexis, DTX Studio, Kerr, Metrex, Total Care, Pentron, Optibond, Harmonize, Sonicfill, Sybron Endo, and CaviWipes to dental offices, clinics, and hospitals. Envista Holdings Corporation was incorporated in 2018 and is headquartered in Brea, California.

PROCEPT BioRobotics stock logo

PROCEPT BioRobotics NASDAQ:PRCT

$58.88 +0.43 (+0.73%)
As of 12:42 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.

TransMedics Group stock logo

TransMedics Group NASDAQ:TMDX

$125.98 -0.43 (-0.34%)
As of 12:43 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.